Abstract: Objective To investigate the relationship between Ki-67 and clinical，pathological and molybdenum target BI- RADS grading of breast cancer. Methods Clinical data of 199 female patients with breast cancer treated in Xiaogan Central Hospital from January 2015 to December 2016 were retrospectively analyzed，including clinical，pathological and molybdenum target BI-RADS classification. Results Ki- 67 labeling index was correlated with tumor diameter ，lymph node metastasis status，molybdenum target BI- RADS grading，ER，PR，HER- 2 and WHO grading of invasive ductal carcinoma （all P values <0.05），uncorrelated with age （P>0.05）. The average Ki- 67 labeling index value of medullary carcinoma（61.47%）was greater than that of the invasive ductal carcinoma（36.26%）， mucinous carcinoma（15.10%），invasive lobular carcinoma（20.62%）and ductal carcinoma（12.53%）（all P values <0.05）；The average Ki-67 index value of invasive ductal carcinoma was higher than that of mucinous carcinoma and ductal carcinoma（all P values <0.05）. The average Ki-67 index value of luminal A subtype（7.23%）was significantly lower than that of luminal B（35.43%），HER- 2 overexpression （39.58%）and triple negative（57.26%）subtypes（P<0.05 for all）. The average value of Ki-67 index in luminal B subtype was less than that in HER-2 overexpression subtype（P<0.05）. The mean value of Ki-67 index of triple-negative subtype were higher than those of non-triple-negative subtype（30.20%）（P<0.05）. Conclusion Ki- 67 level was related to the clinical，pathological and molybdenum target BI-RADS grading of breast cancer patients，and it has some guidling significance for the treatment and prognosis of breast cancer.

Key words: molybdenum target, breast cancer, Ki-67

摘要： 目的 探究Ki-67与乳腺癌患者临床、病理及钼靶BI-RADS分级的关系。方法 回顾性分析2015年1月~2016年12月孝感市中心医院甲乳外科收治的199例女性乳腺癌患者的临床、病理及钼靶BI-RADS分级资料。结果 Ki-67指数与肿瘤直径、淋巴结转移情况、钼靶BI-RADS分级、ER、PR、HER-2及浸润性导管癌WHO分级均有关（均P<0.05），与年龄无关（P>0.05）。髓样癌Ki-67指数平均值（61.47%）大于浸润性导管癌（36.26%）、粘液癌（15.10%）、浸润性小叶癌（20.62%）及导管内癌（12.53%）（均P<0.05）。浸润性导管癌Ki-67指数平均值大于粘液癌及导管内癌（均P<0.05）。LuminalB型（35.43%）、HER-2阳性型（39.58%）及三阴性型（57.26%）Ki-67平均值均大于LuminalA型（7.23%）（均P<0.05），LuminalB型Ki-67平均值小于HER-2阳性型（P<0.05）。三阴性型Ki-67平均值大于非三阴性型（30.20%）（P<0.05）。结论 Ki-67指数与乳腺癌患者临床、病理及钼靶BI-RADS分级均有关，对乳腺癌的治疗和判断预后具有指导意义。

关键词: 乳腺癌, 钼靶, KI-67